Indivior ( (GB:INDV) ) has shared an announcement.
Indivior has announced that the FDA approved label changes for its SUBLOCADE® injection, a treatment for moderate to severe opioid use disorder (OUD). The changes include a rapid initiation protocol that reduces the time to treatment from one week to one hour, and alternative injection sites, enhancing flexibility and potentially improving patient adherence. These updates reflect Indivior’s commitment to patient-centered care and may streamline treatment, offering significant benefits for healthcare providers and patients seeking effective OUD management.
More about Indivior
Indivior is a global pharmaceutical company focused on developing treatments for substance use disorders (SUD). Headquartered in Richmond, VA, it aims to transform SUD from a global crisis into a recognized and treated chronic disease. The company employs over 1,000 people worldwide and offers a portfolio that spans over 30 countries.
YTD Price Performance: -32.76%
Average Trading Volume: 292,258
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: £856.8M
See more data about INDV stock on TipRanks’ Stock Analysis page.